Single-cell genotyping of MDS/CMML clonal output, VTE risk in diffuse glioma, and Del(1p32) is an adverse prognostic factor in myeloma
Blood Podcast
00:00
The Risk of VTE Prophylaxis in Glioma
The optimal timing or duration of VTE prophylaxis in glioma remains unknown. Tumor expression of tissue factor and podoplanein both correlated with VTE. Patients with IDH1 and IDH2 mutations had fewer VTE events. The study provides evidence-based guidelines for clinicians to mitigate the risk of VTE in this cancer.
Transcript
Play full episode
